Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAG-01 in Patients With Non-muscle-invasive Bladder Cancer
NCT06351904Phase 1Recruiting
- Sponsor
- Ractigen Therapeutics
- Start
- Apr 2024
- Primary completion
- Aug 2028
- Modality
- Small RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RAG-01 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ractigen Therapeutics. Primary endpoints: Safety and tolerability of RAG-01 at 6 months and Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) at 21 days. Started Apr 2024; status: recruiting.
02
Drugs
RAG-01
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06351904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06351904.